Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the app...
January 06 2020 - 7:30AM
At Gilead, Mr. Alton has been Chief Patient Officer and Executive
Vice President of International Operations and Corporate Affairs,
Executive Vice President of Corporate and Medical Affairs,
Secretary and Chief Compliance Officer and General Counsel.
Through these and other positions, he was deeply engaged in growing
Gilead from a small biotech to one of the largest pharmaceutical
companies in the world. He was also instrumental in expanding
access to life saving products throughout the world.
Dr. Brosgart brings a deep scientific and biotechnology expertise
in hepatitis, HIV, and other areas central to Enochian’s
pipeline. Enochian recently announced it entered into an
Agreement in Principle to acquire an exclusive license for a novel
approach to potentially treat Hepatitis B infection. Her
academic experience includes her current position as a Clinical
Professor at UCSF and past Senior Vice President and Chief Medical
Officer of Children’s Hospital and Research Center, Oakland,
California. Combined with her past role as Chief Medical
Officer of Alios BioPharma and several roles at Gilead Biosciences,
most recently as Vice President of Medical Affairs and Global
Medical Director of Hepatitis, Dr. Borsgart has overseen numerous
clinical trials. She has been a member of several biotech
Boards and Scientific Advisory Boards. Luc Dubruyne, former
President Global Vaccines GlaxoSmithKline, announced his retirement
from the board due to his recent acceptance of a role in his home
country of Belgium that created a conflict of interest. Mr.
Dubruyne said, “I joined Enochian because of the innovative science
and focus on translating that science into life-saving
products. During my time, strong management and governance
structures have been established. Unfortunately, a new
commitment does not allow me to remain on the Board, but I look
forward to following Enochian’s progress.”
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” plans,” “expects,”
“aims,” “intends” or similar expressions. Actual events or results
may differ materially from those projected in any of such
statements due to various uncertainties, including as set forth in
Enochian’s most recent Annual Report on Form 10-K filed with the
SEC. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
All forward-looking statements are qualified in their entirety by
this cautionary statement, and Enochian undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024